drugset / Trial / NCT01994590
Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if adding dovitinib to the combination of abiraterone acetate and prednisone may help to control metastatic CRPC. The safety of this drug combination will also be studied.
Timeline
- Start
- 2014-05-19
- Primary completion
- 2017-06-05
- Completion
- 2017-06-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiraterone acetate | Small molecule | 1000 mg | Oral |
| Subject | Dovitinib | Small molecule | 400 mg | Oral |
| Background | Prednisone | Other / unclassified | 5 mg | Oral |